Salute e Benessere

Inside information: Bioretec Ltd's Board of Directors resolved on a rights issue…

TAMPERE, Finland, May 28, 2025 /PRNewswire/ -- The Board of Directors of Bioretec Ltd ("Bioretec" or the "Company") has today 28 May 2025, based on the authorisation of the Annual General Meeting of the Company held on 21 March 2025, resolved to offer Bioretec's shareholders up to 6,156,618 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the…
PR Newswire
28/05/2025

CPHI & PMEC China Sees Surge in International Attendance as Global Pharma Trade…

The event's surge in global interest coincides with easing trade tariffs, improved pharmaceutical valuations, and increased capital expenditure across the sector. International executives are attending in record numbers, seeking new ingredient suppliers and equipment providers in China's robust manufacturing ecosystem. The event's surge in global interest coincides with easing trade tariffs, improved pharmaceutical valuations, and increased capital expenditure across the sector. International...
PR Newswire
28/05/2025

Long-term Commitment to Treating Endometriosis and Improving Women's Quality of…

Being Platinum Sponsors of WCE enabled us to show our dedication to endometriosis care with holistic, patient-centric mindset addressing both physical and emotional dimensions of women's health. Endometriosis is a chronic, painful condition affecting over 190 million women worldwide, with an ever-increasing prevalence rate. It occurs when tissue similar to the lining of the uterus grows outside the uterine cavity, leading to inflammation, scarring, and significant pain. Being Platinum…
PR Newswire
28/05/2025

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three…

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
Nasdaq GlobeNewswire
28/05/2025

Sampled Renews MIA (IMP) License with MHRA Certification

Companies must partner with a MIA (IMP) licensed provider to meet these demands for import into the UK. This accreditation enables the storage and distribution of IMPs and facilitates the exchange of IMPs with other licensed entities through a Qualified Person. Finding an MHRA-certified partner who meets the highest standards of trust and quality is essential. Choosing the wrong partner can put clinical trials at risk through diminished IMP quality and regulatory non-compliance. Companies…
PR Newswire
28/05/2025

Shareholders vote in favor of all proposals by the Board at Idorsia's Annual…

Allschwil, Switzerland – May 28, 2025At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.The meeting was attended by 166 shareholders, representing a total of 97'748'740 shares, or 43.28% of the total outstanding shares.Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update. Jean-Paul Clozel, MD, Chairman of the Board of...
Nasdaq GlobeNewswire
28/05/2025

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. 1.Details of the person discharging managerial responsibilities/person closely associated NamePeter Karlstromer 2.Reason for the notification Position/statusChief Executive Officer ...
Nasdaq GlobeNewswire
28/05/2025

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

A recognized thought leader in bioanalysis and immunogenicity from discovery through commercialization, Dr. Jawa has authored over 100 peer-reviewed publications and holds prominent roles in various renowned scientific societies and consortiums, including AAPS, IQ, SC, and EIP. She was named an AAPS fellow in 2022 for her significant contributions. A recognized thought leader in bioanalysis and immunogenicity from discovery through commercialization, Dr. Jawa has authored over 100...
PR Newswire
28/05/2025

Gardening Market Worth USD 150 Billion by 2030 - Industry Size, Trends…

Interested User Can Get a FREE PDF sample of the report here - https://www.marknteladvisors.com/query/request-sample/gardening-market.html Interested User Can Get a FREE PDF sample of the report here -https://www.marknteladvisors.com/query/request-sample/gardening-market.html Moreover, the incorporation of smart gardening tools, including automated irrigation systems and soil sensors, is democratizing gardening. This trend, combined with the DIY gardening culture driven by social media,...
PR Newswire
28/05/2025

Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected…

Following its selection, KT-939 will be displayed alongside the pioneering products from global leaders like Ashland, DSM-Firmenich, Croda, Lubrizol, and Eastman, attracting attentions from key industry stakeholders across branding, R&D, and formulation and aligning with current hot trends such as sustainability, biotechnology, and personalized care. Meanwhile, the Inspiration Hive, as a high-end communication platform, will enable KT-939 to explore collaboration opportunities, establish new…
PR Newswire
28/05/2025

Sobi to share new clinical data and research at EULAR 2025

"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs…
PR Newswire
28/05/2025

Sectra equips multi-site US health system with enterprise imaging as a cloud…

Sectra One Cloud and Sectra Amplifier Service are cloud services fully managed by Sectra. This means that the health system receives an AI-enabled enterprise imaging solution that Sectra monitors, optimizes, and manages. With Sectra Amplifier Service, they can integrate third-party AI applications into clinical workflows. It allows all applications to run on a single, unified infrastructure, eliminating the need to manage multiple separate systems, in turn reducing security risks. Sectra takes…
PR Newswire
28/05/2025

Duni Group and Musée de la Toile de Jouy Unite in a Unique Design Collaboration

- "We are deeply honored and inspired to collaborate with Musée de la Toile de Jouy. Their rich design heritage meets our passion for sustainable table setting - together, we have created something both beautiful and meaningful. We hope this collection sparks curiosity, joy, and fosters new stories around the table," says Karen Marini, Marketing and Brands Manager, Duni Group. - "We are deeply honored and inspired to collaborate with Musée de la Toile de Jouy. Their rich design…
PR Newswire
28/05/2025

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for…

"The FDA's Fast Track Designation for EBC-129 underscores the promise of this novel ADC in addressing the critical need for expanded treatment options for PDAC patients and represents an important step in our efforts to accelerate its development. We view this as both a validation of our efforts and a responsibility to move decisively to advance EBC-129 as a new option to patients in need," said Professor Damian O'Connell, Chief Executive Officer of EDDC. "The FDA's Fast Track…
PR Newswire
28/05/2025

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

PARIS and CAMBRIDGE, Mass., May28, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025 Time: 3:45 pm EDT / 9:45 pm...
Nasdaq GlobeNewswire
28/05/2025

Pharming Group to participate in June investor conferences

Leiden, the Netherlands, May 28, 2025:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June:Jefferies Global Healthcare Conference 2025, New York, USA, June 4-5, 2025Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Thursday, June 5 at 2:00 pm EDT/20:00 CEST. A live webcast and replay of the presentation...
Nasdaq GlobeNewswire
28/05/2025

2025 World Brain Day Dedicated to Brain Health for All Ages

Neurological disorders remain the leading cause of disability-adjusted life years (DALYs) and the second leading cause of death globally. Yet many of these conditions can be prevented, or better managed with early intervention, education, and equitable access to care. This year's campaign emphasizes five key messages: awareness, education, prevention, access, and advocacy. Neurological disorders remain the leading cause of disability-adjusted life years (DALYs) and the second leading cause of...
PR Newswire
28/05/2025

IonOpticks Generation 4 Aurora Series® sets a new benchmark in chromatography

Today also marks the introduction of IonOpticks' HeatSync™ product family, developed to provide a more efficient and user-friendly suite of accessories for column heating at the source. The HeatSync™ ecosystem enables precise temperature control and includes a controller, column heater, regulator, and a dedicated housing for columns shorter than 8 cm. Its streamlined design minimises complexity, allowing researchers to focus on scientific discovery rather than managing equipment. Today also...
PR Newswire
28/05/2025

FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment…

Travere Therapeutics' FILSPARI (sparsentan) Overview Travere Therapeutics' FILSPARI (sparsentan) Overview FILSPARI (sparsentan) is a once-daily oral treatment that uniquely targets two key pathways, endothelin-1 and angiotensin II (also known as DEARA), in the progression of IgA nephropathy. It is the first approved non-immunosuppressive therapy for this condition. Endothelin-1 and angiotensin II contribute to kidney function decline by promoting inflammation and fibrosis, altering...
PR Newswire
27/05/2025

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac diseaseCandidate demonstrates Teva's commitment to bringing important new treatment options to underserved patient populationsTEL AVIV, Israel, May27, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug...
Nasdaq GlobeNewswire
27/05/2025

Galapagos Creates New Subscription Right Plan

Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created,...
Nasdaq GlobeNewswire
27/05/2025

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs…

Jefferies Global Healthcare ConferenceChris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical Officer Wednesday, June 4, 2025, at 9:20 am ET Goldman Sachs 46 thAnnual Global Healthcare ConferenceRichard Francis, President & CEO Tuesday, June 10, 2025, at 8:00 am ET To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the...
Nasdaq GlobeNewswire
27/05/2025

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, May 27, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares…
Nasdaq GlobeNewswire
27/05/2025

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference…

Daix (France), New York City (New York, United States), May 27, 2025– Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a...
Nasdaq GlobeNewswire
27/05/2025
Altri  Comunicati